<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-93347" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Repaglinide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Milner</surname>
            <given-names>Zara</given-names>
          </name>
          <aff>Cardiff University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Akhondi</surname>
            <given-names>Hossein</given-names>
          </name>
          <aff>University of Nevada</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Zara Milner declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hossein Akhondi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-93347.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Repaglinide is a medication used in the management and treatment of diabetes mellitus Type 2. It is in the antihyperglycemic class of drugs. This activity outlines the indications, mechanism of action, and contraindications for repaglinide as a valuable agent in the management of diabetes mellitus type 2.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of repaglinide.</p></list-item><list-item><p>Identify the adverse drug reactions associated with repaglinide.</p></list-item><list-item><p>Review the role of repaglinide in treatment algorithms for managing diabetes mellitus type 2.</p></list-item><list-item><p>Outline the importance of collaboration and coordination among the interprofessional team and how it can enhance patient care when dosing and monitoring repaglinide. This will improve patient outcomes for patients receiving antihyperglycemic agents.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=93347&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=93347">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-93347.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Repaglinide is a drug used in the treatment of diabetes mellitus type 2. It belongs to a class of antihyperglycemic agents known as meglitinides, along with nateglinide. Meglitinides work to reduce blood glucose levels by stimulating endogenous insulin production. The present recommended starting dose is dependent on hemoglobin A1c levels, with those below 8% (64 mmol/mol) urged to start with 0.5 mg pre-prandially and those above 8% to start with 1 to 2 mg.&#x000a0;</p>
        <p>Repaglinide may be used as monotherapy (supplemental to exercise and diet control) or in combination with other antihyperglycemic agents (metformin or others, if metformin is not tolerated/contraindicated). The exception is using sulfonylureas (e.g., gliclazide, glipizide), which is a contraindication for dual therapy with meglitinides. Research has suggested that repaglinide is a favorable treatment choice in patients with chronic kidney disease and end-stage renal disease.&#x000a0;</p>
        <p>Repaglinide is FDA class C during pregnancy, meaning its use requires caution. There has been no evidence to support its safe use during breastfeeding, and thus an alternative is recommended.&#x000a0;</p>
        <p>The safety of repaglinide in children under the age of 18 has not been established and, as such, is not recommended.&#x000a0;</p>
        <p>Repaglinide should be taken shortly before meals and should be omitted when skipping meals.<xref ref-type="bibr" rid="article-93347.r1">[1]</xref><xref ref-type="bibr" rid="article-93347.r2">[2]</xref><xref ref-type="bibr" rid="article-93347.r3">[3]</xref><xref ref-type="bibr" rid="article-93347.r4">[4]</xref><xref ref-type="bibr" rid="article-93347.r5">[5]</xref><xref ref-type="bibr" rid="article-93347.r6">[6]</xref></p>
      </sec>
      <sec id="article-93347.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Repaglinide is an insulin secretagogue, meaning it binds to receptors on pancreatic beta cells and stimulates insulin release. Repaglinide&#x000a0;binds to an ATP-dependent potassium channel on beta cells, known as SUR1, bringing about its closure. This mechanism of action is similar to that of the sulfonylureas, and as a result, the concurrent use of these therapies is contraindicated.&#x000a0;</p>
        <p>Repaglinide demonstrates a concentration-response relationship in the presence of glucose, with a maximal secretory response of approximately 10 nmol/L. Studies suggest repaglinide reduces postprandial glucose in the order of around 5.8 mmol/L and fasting glucose around 3.1&#x000a0;to 3.4 mmol/L.</p>
        <p>Repaglinide is rapidly absorbed, with a half-life of fewer than 60 minutes. The fast onset and short duration of action of repaglinide have made it one of the most appropriate therapies for managing postprandial glucose spikes, and as such, it is recommended approximately 30 minutes before an intended meal.</p>
        <p>In the body, repaglinide binds to albumin at around 98% concentration&#x000a0;and is associated with a more significant reduction in glycated albumin than sulfonylureas.&#x000a0;</p>
        <p>Repaglinide is inactivated and excreted via the liver, and as such, concomitant use of other therapies associated with liver metabolism should be considered.<xref ref-type="bibr" rid="article-93347.r7">[7]</xref><xref ref-type="bibr" rid="article-93347.r8">[8]</xref><xref ref-type="bibr" rid="article-93347.r9">[9]</xref><xref ref-type="bibr" rid="article-93347.r10">[10]</xref><xref ref-type="bibr" rid="article-93347.r11">[11]</xref><xref ref-type="bibr" rid="article-93347.r12">[12]</xref></p>
      </sec>
      <sec id="article-93347.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Oral administration of repaglinide, between 0.5 to 4 mg twice to three times daily, to a maximum of 16 mg, produces glycemic control in a similar order to other antihyperglycemic agents. Repaglinide should be administered approximately 30 minutes before an intended meal, and&#x000a0;the dose skipped if a scheduled mealtime is skipped. Dose adjustments should be reviewed a minimum of one week later.<xref ref-type="bibr" rid="article-93347.r2">[2]</xref><xref ref-type="bibr" rid="article-93347.r5">[5]</xref><xref ref-type="bibr" rid="article-93347.r13">[13]</xref></p>
      </sec>
      <sec id="article-93347.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most commonly reported side effect associated with repaglinide monotherapy is hypoglycemia (7% in a study of 76 patients), followed by weight gain (1.8 kg / 16 weeks). Whipple triad for hypoglycemia is defined as the presence of symptoms of hypoglycemia, presence of factual hypoglycemia (&#x0003c;50 mg/dl), and correction of the symptoms after administration of glucose.&#x000a0;</p>
        <p>Repaglinide has reports showing it to be of greater risk of cardiovascular events than metformin but lesser than sulfonylureas.</p>
        <p>Other adverse reactions of note included upper respiratory tract infection and sinusitis when trialed versus placebo. There are reports of weight gain, diarrhea, and joint pain.&#x000a0;</p>
        <p>Reports of hypoglycemia are more frequent when repaglinide is used in combination with metformin, while studies suggest an increased risk of peripheral edema if used in combination with a thiazolidinedione.<xref ref-type="bibr" rid="article-93347.r14">[14]</xref><xref ref-type="bibr" rid="article-93347.r15">[15]</xref><xref ref-type="bibr" rid="article-93347.r16">[16]</xref><xref ref-type="bibr" rid="article-93347.r17">[17]</xref></p>
      </sec>
      <sec id="article-93347.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Repaglinide is not contraindicated in many instances - it has been utilized in patients with chronic kidney disease to good effect. It is deemed safer in such cases than metformin and sulfonylureas.</p>
        <p>Contraindications does include<xref ref-type="bibr" rid="article-93347.r13">[13]</xref><xref ref-type="bibr" rid="article-93347.r6">[6]</xref><xref ref-type="bibr" rid="article-93347.r18">[18]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity to any of the components of the oral preparation</p>
          </list-item>
          <list-item>
            <p>Diabetes mellitus type 1 and diabetic ketoacidosis</p>
          </list-item>
          <list-item>
            <p>Severe liver dysfunction</p>
          </list-item>
          <list-item>
            <p>Concomitant use of gemfibrozil or clopidogrel</p>
          </list-item>
          <list-item>
            <p>Concomitant use of NPH insulin</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-93347.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Periodic measurements of fasting glucose and HBA1c are recommended for determining the efficacy of treatment. Dose adjustments should be monitored by fasting glucose alone for responsivity at a minimum of 1 week following the start of treatment.<xref ref-type="bibr" rid="article-93347.r5">[5]</xref></p>
        <p>Repaglinide is metabolized by the hepatic isoenzymes CYP3A4&#x000a0;and CYP2C8. As such, it carries a low therapeutic index as a substrate for inactivation and clearance and is susceptible to concentration changes in the presence of hepatic inducers and inhibitors.&#x000a0;</p>
        <p>Dose adjustment and closer monitoring may be necessary for concomitant use of the following therapeutic agents:</p>
        <list list-type="bullet">
          <list-item>
            <p>Fenofibrate</p>
          </list-item>
          <list-item>
            <p>Ketoconazole</p>
          </list-item>
          <list-item>
            <p>Trimethoprim</p>
          </list-item>
          <list-item>
            <p>Cyclosporine</p>
          </list-item>
          <list-item>
            <p>Rifampin</p>
          </list-item>
          <list-item>
            <p>Estrogen-based therapies</p>
          </list-item>
          <list-item>
            <p>Simvastatin</p>
          </list-item>
          <list-item>
            <p>Nifedipine</p>
          </list-item>
          <list-item>
            <p>Clarithromycin</p>
          </list-item>
        </list>
        <p>Besides, grapefruit juice may cause pharmacokinetic interactions.<xref ref-type="bibr" rid="article-93347.r19">[19]</xref><xref ref-type="bibr" rid="article-93347.r20">[20]</xref><xref ref-type="bibr" rid="article-93347.r5">[5]</xref></p>
      </sec>
      <sec id="article-93347.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Severe hypoglycemia may induce seizures, coma, or other neurological impairments and requires immediate hospitalization and medical attention.&#x000a0;</p>
        <p>Hypoglycemia without loss of consciousness may present with drowsiness, confusion, profuse sweating, agitation, abdominal pain, and tachycardia.</p>
        <p>Intentional overdose in large quantities may be managed with activated charcoal if caught exceptionally early. In the asymptomatic patient, a watch-and-wait approach with repeated blood glucose measurements for 24 hours may suffice. It is important to note that despite the short duration of action, overdose with repaglinide may lead to more prolonged hypoglycemia.</p>
        <p>In unintentional excessive ingestion, prompt feeding may be sufficient to alleviate symptoms. In more severe cases, glucagon subcutaneous or intramuscular injection is recommended (1 mg for weights greater than 25 kg). Failure to respond to glucagon should be addressed with a 20% glucose intravenous infusion.<xref ref-type="bibr" rid="article-93347.r21">[21]</xref><xref ref-type="bibr" rid="article-93347.r22">[22]</xref></p>
      </sec>
      <sec id="article-93347.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Management of diabetes mellitus type 2 is an interprofessional process with the patient at the center of care.</p>
        <p>All treatment should consider the patients' preferences, and patients should always be well informed and encouraged to make their own decisions about their care.</p>
        <p>Patient education is key to the management of diabetes mellitus type 2, and it is the healthcare professional's responsibility to ensure all guidance is evidence-based, goal-oriented, and suitably informative.<xref ref-type="bibr" rid="article-93347.r17">[17]</xref><xref ref-type="bibr" rid="article-93347.r5">[5]</xref></p>
        <p>Evidence has suggested that educating patients on the self-management of their diabetes leads to improved clinical outcomes, as does input from specialists outside of the medical team, including but not limited to dieticians and occupational therapists. Information regarding possible drug-drug interactions, dosing alterations, and organ failure prevention is provided by specialists.<xref ref-type="bibr" rid="article-93347.r23">[23]</xref><xref ref-type="bibr" rid="article-93347.r24">[24]</xref></p>
        <p>Research suggests there may be benefits in switching to repaglinide from other antihyperglycemic agents in the elderly. Pharmacists and specialists should&#x000a0;be trained in providing adequate education, risks versus benefits, and support clinicians (MDs) DOs, NPs, PAs) in making this transition. The interprofessional approach will yield improved patient results with targeted medication management and reduce adverse events.<xref ref-type="bibr" rid="article-93347.r25">[25]</xref><xref ref-type="bibr" rid="article-93347.r26">[26]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-93347.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=93347&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=93347">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/93347/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=93347">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-93347.s11">
        <title>References</title>
        <ref id="article-93347.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <chapter-title>Repaglinide</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>2</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">30000151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gomis</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Repaglinide as monotherapy in Type 2 diabetes.</article-title>
            <source>Exp Clin Endocrinol Diabetes</source>
            <year>1999</year>
            <volume>107 Suppl 4</volume>
            <fpage>S133</fpage>
            <page-range>S133-5</page-range>
            <pub-id pub-id-type="pmid">10522838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Owens</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.</article-title>
            <source>Diabet Med</source>
            <year>1998</year>
            <volume>15 Suppl 4</volume>
            <fpage>S28</fpage>
            <page-range>S28-36</page-range>
            <pub-id pub-id-type="pmid">9868989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mollar-Puchades</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Martin-Cortes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perez-Calvo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Diaz-Garcia</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Use of repaglinide on a pregnant woman during embryogenesis.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>146</fpage>
            <page-range>146-7</page-range>
            <pub-id pub-id-type="pmid">17199735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landgraf</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Meglitinide analogues in the treatment of type 2 diabetes mellitus.</article-title>
            <source>Drugs Aging</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>411</fpage>
            <page-range>411-25</page-range>
            <pub-id pub-id-type="pmid">11190420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Soma</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.</article-title>
            <source>Curr Drug Metab</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-69</page-range>
            <pub-id pub-id-type="pmid">21303332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatorp</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics and pharmacodynamics of repaglinide.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2002</year>
            <volume>41</volume>
            <issue>7</issue>
            <fpage>471</fpage>
            <page-range>471-83</page-range>
            <pub-id pub-id-type="pmid">12083976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plosker</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Figgitt</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.</article-title>
            <source>Pharmacoeconomics</source>
            <year>2004</year>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>389</fpage>
            <page-range>389-411</page-range>
            <pub-id pub-id-type="pmid">15099124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nattrass</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lauritzen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?</article-title>
            <source>Int J Obes Relat Metab Disord</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>24 Suppl 3</volume>
            <fpage>S21</fpage>
            <page-range>S21-31</page-range>
            <pub-id pub-id-type="pmid">11063281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malaisse</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.</article-title>
            <source>Treat Endocrinol</source>
            <year>2003</year>
            <volume>2</volume>
            <issue>6</issue>
            <fpage>401</fpage>
            <page-range>401-14</page-range>
            <pub-id pub-id-type="pmid">15981944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sunaga</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gonoi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shibasaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ichikawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kusama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seino</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2001</year>
            <month>Nov</month>
            <day>09</day>
            <volume>431</volume>
            <issue>1</issue>
            <fpage>119</fpage>
            <page-range>119-25</page-range>
            <pub-id pub-id-type="pmid">11716850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seedher</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kanojia</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Reversible binding of antidiabetic drugs, repaglinide and gliclazide, with human serum albumin.</article-title>
            <source>Chem Biol Drug Des</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>290</fpage>
            <page-range>290-6</page-range>
            <pub-id pub-id-type="pmid">18844675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Owens</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>McDougall</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Repaglinide: prandial glucose regulation in clinical practice.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>2 Suppl 1</volume>
            <fpage>S43</fpage>
            <page-range>S43-8</page-range>
            <pub-id pub-id-type="pmid">11225759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azimova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>San Juan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular safety profile of currently available diabetic drugs.</article-title>
            <source>Ochsner J</source>
            <year>2014</year>
            <season>Winter</season>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>616</fpage>
            <page-range>616-32</page-range>
            <pub-id pub-id-type="pmid">25598727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hassman</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Madder</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Brazinsky</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Khutoryansky</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hale</surname>
                <given-names>PM</given-names>
              </name>
              <collab>Repaglinide Versus Nateglinide Comparison Study Group</collab>
            </person-group>
            <article-title>Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.</article-title>
            <source>Diabetes Care</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>1265</fpage>
            <page-range>1265-70</page-range>
            <pub-id pub-id-type="pmid">15161773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cho</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Ngo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YB</given-names>
              </name>
            </person-group>
            <article-title>Bioequivalence of a fixed-dose repaglinide/metformin combination tablet and equivalent doses of repaglinide and metformin tablets&#x02029;.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>292</fpage>
            <page-range>292-300</page-range>
            <pub-id pub-id-type="pmid">29648532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Omori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nomoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takase</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Manda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kurihara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Atsumi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miyoshi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea.</article-title>
            <source>J Diabetes Investig</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>367</fpage>
            <page-range>367-374</page-range>
            <pub-id pub-id-type="pmid">29963781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zanchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lehmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Philippe</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology.</article-title>
            <source>Swiss Med Wkly</source>
            <year>2012</year>
            <volume>142</volume>
            <fpage>w13629</fpage>
            <pub-id pub-id-type="pmid">22987488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheen</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2007</year>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-108</page-range>
            <pub-id pub-id-type="pmid">17253883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marshall</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wilton</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shakir</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study.</article-title>
            <source>Acta Diabetol</source>
            <year>2006</year>
            <month>May</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-13</page-range>
            <pub-id pub-id-type="pmid">16710643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spiller</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Management of antidiabetic medications in overdose.</article-title>
            <source>Drug Saf</source>
            <year>1998</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>411</fpage>
            <page-range>411-24</page-range>
            <pub-id pub-id-type="pmid">9825953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elling</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spehl</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wohlfarth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Auwaerter</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hermanns-Clausen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prolonged hypoglycemia after a suicidal ingestion of repaglinide with unexpected slow plasma elimination.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2016</year>
            <volume>54</volume>
            <issue>2</issue>
            <fpage>158</fpage>
            <page-range>158-60</page-range>
            <pub-id pub-id-type="pmid">26692235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benson</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Sidebottom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Miedema</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Boucher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vacquier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sillah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gamam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>VanWormer</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Impact of ENHANCED (diEtitiaNs Helping pAtieNts CarE for Diabetes) Telemedicine Randomized Controlled Trial on Diabetes Optimal Care Outcomes in Patients with Type 2&#x000a0;Diabetes.</article-title>
            <source>J Acad Nutr Diet</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>119</volume>
            <issue>4</issue>
            <fpage>585</fpage>
            <page-range>585-598</page-range>
            <pub-id pub-id-type="pmid">30711463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adam</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Evaluating the Impact of Diabetes Self-Management Education Methods on Knowledge, Attitudes and Behaviours of Adult Patients With Type 2 Diabetes Mellitus.</article-title>
            <source>Can J Diabetes</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>470</fpage>
            <page-range>470-477.e2</page-range>
            <pub-id pub-id-type="pmid">29449096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Sheu</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Tai</surname>
                <given-names>TY</given-names>
              </name>
            </person-group>
            <article-title>Team care of type 2 diabetes mellitus in Taiwan.</article-title>
            <source>Diabetes Res Clin Pract</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>106 Suppl 2</volume>
            <fpage>S309</fpage>
            <page-range>S309-13</page-range>
            <pub-id pub-id-type="pmid">25550059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-93347.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valensi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Picard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pathak</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Type 2 diabetes: Why should diabetologists and cardiologists work more closely together?</article-title>
            <source>Diabetes Metab</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>501</fpage>
            <page-range>501-504</page-range>
            <pub-id pub-id-type="pmid">31394190</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
